IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Evgeny NUDLER et al

Appln. No.: Not yet assigned

Appln. No.: Not yet assigned

Filed: September 17, 2003

For: CONTROL OF NITRIC OXIDE

BIOACTIVITY ...

Art Unit:

Confirmation No.

Washington, D.C.

September 17, 2003

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §\$1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR \$1.97, as it is filed within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application; and before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

2. In accordance with 37 CFR \$1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office,

In re Appln. No.

either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except documents AA-AG are U.S. patent(s) and/or published applications. As this is a U.S. application filed after June 30, 2003, or an entry into national stage under 35 USC \$371 after June 30, 2003, the requirement to file copies of such U.S. patents or published applications has been waived. (Office of Patent Legal Administration - Pre O.G. Notice of July 11, 2003).

3.No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4.In accordance with 37 CFR §\$1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in \$1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:

Anne M. Kornbau Reg. No. 25,884

AMK:qsk

624 Ninth Street, N.W., Suite 300 Washington, D.C. 20001-5303 Telephone: (202) 628-5197

Facsimile: (202)737-3528

G:\BN\N\nyum\Nudler 2A\PTO\IDS.doc

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known		
				Application Number	Not yet assigned	
			LOSURE	Filing Date	September 17, 2003	
			PLICANT	First Named Inventor	Evgeny NUDLER	
				Group Art Unit		
(use as many sheets as necessary)			ecessary)	Examiner Name		
Sheet	1	of	2	Attorney Docket Number	NUDLER2A	

			U.S. PA	TENT DOCUMENTS	
Examiner nitials*	Cite No.1	Document Number Number-Kind Code ^{2 (8 known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,204,296	03-20-2001	Jeffry Greg WEERS et al	
	АВ	US-6,289,892	09-18-2001	Nicholas Simon FAITHFULL et al	
	AC	US-6,166,092	12-26-2000	K. Michael SEKINS et al	
	AD	US-5,684,050	11-04-1997	Leland C. CLARK, Jr. et al	
	AE	US-5,514,720	05-07-1996	Leland C. CLARK, Jr. et al	
	AF	US-5,621,144	04-15-1997	Stephen R. COOPER	
	AG	US-5,869,539	02-09-1999	R.E. GARFIELD et al	
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Number Country Code ³ Number ⁵ Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶		

Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Compl te if Known			
				Application Number	Not yet assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			LOSURE	Filing Date	September 17, 2003
			PLICANT	First Named Inventor	Evgeny NUDLER
				Group Art Unit	
			ecessary)	Examiner Name	
Sheet	2	of		Attorney Docket Number	NUDLER2A

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	AH	"Regulation of Basal Myocardial Function by NO," <u>Cardiovascular Research</u> , Georg KOJDA et al, 1999	
	Al	"Potential Therapeutic Uses for S-Nitrosothiols," Clinical Science, G. RICHARDSON et al, 2002	
	AJ	"S-Nitrosothiols: A Class of Nitric Oxide-Donor Drugs," Clinical Science, Haitham AL-SA'DONI et al, 2000	
	AK	"Selective Pharmacological Inhibition of Distinct Nitric Oxide Synthase Isoforms," <u>Biochemical Pharmacology,</u> Vol. 51, Garry J. SOUTHAN et al, 1996	
	AL	"Effects of Nitric Oxide Synthase Blockers on Renal Function," Nephrol Dial Transplant, Francis B. GABBAI, 2001.	
	AM	"Is Nitric Oxide Overproduction the Target of Choice for the Management of Septic Shock?," Pharmacology & Therapeutics, Vol. 91, Francois FEIHL et al, 2001	
			لب
Examir Signati		Date Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.